InvestorsHub Logo
Followers 138
Posts 23378
Boards Moderated 0
Alias Born 04/08/2004

Re: None

Friday, 05/24/2024 12:02:03 AM

Friday, May 24, 2024 12:02:03 AM

Post# of 464604
ANAVEX-371 is under clinical development by Anavex Life Sciences and currently in Phase II for Schizophrenia. According to GlobalData, Phase II drugs for Schizophrenia have a 44% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how ANAVEX-371’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks.

https://www.pharmaceutical-technology.com/data-insights/anavex-371-anavex-life-sciences-schizophrenia-likelihood-of-approval/

Good luck and GOD bless,
Bullish
Bullish
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News